MRI cerebral white matter lesions and paraoxonase PON1 polymorphisms : three-year follow-up of the austrian stroke prevention study.
暂无分享,去创建一个
F. Fazekas | H. Hartung | R. Schmidt | H. Schmidt | A. Lechner | P. Kapeller | G. Roob | G. Kostner
[1] T. Manolio,et al. Relationships of cerebral MRI findings to ultrasonographic carotid atherosclerosis in older adults : the Cardiovascular Health Study. CHS Collaborative Research Group. , 1999, Arteriosclerosis, thrombosis, and vascular biology.
[2] R. Schmidt,et al. Paraoxonase PON1 polymorphism leu-Met54 is associated with carotid atherosclerosis: results of the Austrian Stroke Prevention Study. , 1998, Stroke.
[3] J. Miller,et al. Serum paraoxonase (PON1) 55 and 192 polymorphism and paraoxonase activity and concentration in non-insulin dependent diabetes mellitus. , 1998, Atherosclerosis.
[4] D. Shih,et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis , 1998, Nature.
[5] K. Donaghue,et al. A variant of paraoxonase (PON1) gene is associated with diabetic retinopathy in IDDM. , 1998, The Journal of clinical endocrinology and metabolism.
[6] B L Miller,et al. Evidence for genetic variance in white matter hyperintensity volume in normal elderly male twins. , 1998, Stroke.
[7] D. Sanghera,et al. DNA polymorphisms in two paraoxonase genes (PON1 and PON2) are associated with the risk of coronary heart disease. , 1998, American journal of human genetics.
[8] Griendling Kk,et al. Oxidative stress and cardiovascular disease. , 1997 .
[9] R. James,et al. Two alleles of the human paraoxonase gene produce different amounts of mRNA. An explanation for differences in serum concentrations of paraoxonase associated with the (Leu-Met54) polymorphism. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[10] P. Durrington,et al. Presence of paraoxonase in human interstitial fluid , 1997, FEBS letters.
[11] P. Durrington,et al. 3.P.81 Immunolocalisation of paraoxonase with clusterin and apolipoprotein A1 in the human artery wall , 1997 .
[12] D. Sanghera,et al. Genetic polymorphism of paraoxonase and the risk of coronary heart disease. , 1997, Arteriosclerosis, thrombosis, and vascular biology.
[13] R. Alexander,et al. Oxidative stress and cardiovascular disease. , 1997, Circulation.
[14] P. Froguel,et al. Paraoxonase polymorphism Met-Leu54 is associated with modified serum concentrations of the enzyme. A possible link between the paraoxonase gene and increased risk of cardiovascular disease in diabetes. , 1997, The Journal of clinical investigation.
[15] F. Fazekas,et al. Magnetic resonance imaging white matter hyperintensities in clinically normal elderly individuals. Correlations with plasma concentrations of naturally occurring antioxidants. , 1996, Stroke.
[16] B. La Du,et al. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. , 1996, Genomics.
[17] R. Hegele,et al. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins , 1996, Current opinion in lipidology.
[18] A. Marian,et al. A variant of human paraoxonase/arylesterase (HUMPONA) gene is a risk factor for coronary artery disease. , 1995, The Journal of clinical investigation.
[19] A. Boulton,et al. Serum paraoxonase activity, concentration, and phenotype distribution in diabetes mellitus and its relationship to serum lipids and lipoproteins. , 1995, Arteriosclerosis, thrombosis, and vascular biology.
[20] G. Charpentier,et al. Gln-Arg192 polymorphism of paraoxonase and coronary heart disease in type 2 diabetes , 1995, The Lancet.
[21] J. Garcìa,et al. The significance of cerebral white matter abnormalities 100 years after Binswanger's report. A review. , 1995, Stroke.
[22] P. Jennings. From hemobiology to vascular disease: a review of the potential of gliclazide to influence the pathogenesis of diabetic vascular disease. , 1994, Journal of diabetes and its complications.
[23] F. Fazekas,et al. Assessment of cerebrovascular risk profiles in healthy persons: definition of research goals and the Austrian Stroke Prevention Study (ASPS). , 1994, Neuroepidemiology.
[24] A. Hofman,et al. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population‐based study , 1994, Neurology.
[25] E P Steinberg,et al. Magnetic resonance abnormalities and cardiovascular disease in older adults. The Cardiovascular Health Study. , 1994, Stroke.
[26] C. Abbott,et al. Protection of low-density lipoprotein against oxidative modification by high-density lipoprotein associated paraoxonase. , 1993, Atherosclerosis.
[27] F. Fazekas,et al. Pathologic correlates of incidental MRI white matter signal hyperintensities , 1993, Neurology.
[28] A Hofman,et al. Cerebral white matter lesions and atherosclerosis in the Rotterdam Study , 1993, The Lancet.
[29] D. Adler,et al. The molecular basis of the human serum paraoxonase activity polymorphism , 1993, Nature Genetics.
[30] P. Durrington,et al. Paraoxonase prevents accumulation of lipoperoxides in low‐density lipoprotein , 1991, FEBS letters.
[31] D. Harman. The aging process: major risk factor for disease and death. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[32] G Lantos,et al. Brain white-matter changes in the elderly prone to falling. , 1989, Archives of neurology.
[33] J L Witztum,et al. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.
[34] H Lechner,et al. White matter signal abnormalities in normal individuals: correlation with carotid ultrasonography, cerebral blood flow measurements, and cerebrovascular risk factors. , 1988, Stroke.
[35] T. H. Newton,et al. Foci of MRI signal (pseudo lesions) anterior to the frontal horns: histologic correlations of a normal finding. , 1986, AJR. American journal of roentgenology.